Diagnostic performance of osteocalcin measurements in patients with endogenous Cushing’s syndrome
- 15 June 2016
- journal article
- Published by Portico in BoneKEy Reports
- Vol. 5, 815
- https://doi.org/10.1038/bonekey.2016.42
Abstract
The aim of this study was to evaluate the diagnostic performance of osteocalcin (OC), as measured by automated electrochemiluminescence immunoassay (ECLIA), in identifying Cushing's syndrome (CS) in two separate populations: among obese and overweight subjects and among women of postmenopausal age with osteoporosis. Among the 106 referral patients with obesity, CS was confirmed in 42 cases. The patients of the referred population provided late-night salivary cortisol (LNSC), underwent low-dose dexamethasone suppression testing (DST) and were further evaluated until CS was pathologically confirmed. A threshold of OC-8.3 ng ml(-1) differentiated CS among obese and overweight subjects with a sensitivity of 73.8% (95% confidence interval (CI) 58.9-84.7) and a specificity of 96.9% (95% CI 89.3-99.1). The total area under the receiver operating characteristic curve (AUC) was 0.859 (95% CI 0.773-0.945), which was lower than LNSC or DST (P=0.01). In the retrospective portion of the study, the OC levels were evaluated in 67 subjects with newly diagnosed postmenopausal osteoporosis and in 23 patients (older than 45) with newly diagnosed CS and osteoporosis (presence of low traumatic fractures or T-score P-2.5). The diagnostic performance of OC for osteoporosis due to CS was within an AUC of 0.959 (95% CI 0.887-1.00). A threshold for OC of 8.3 ng ml-1 yielded a sensitivity of 95.4% (95% CI 78.2-99.2%) and a specificity of 98.5% (95% CI 92.0-99.7%). Thus, osteocalcin could be used in the diagnostic testing for endogenous hypercortisolism in patients referred to exclude CS and to identify CS among patients of postmenopausal age with osteoporosis.Keywords
This publication has 32 references indexed in Scilit:
- The clinical utility of bone marker measurements in osteoporosisJournal of Translational Medicine, 2013
- European guidance for the diagnosis and management of osteoporosis in postmenopausal womenOsteoporosis International, 2012
- Specificity of Screening Tests for Cushing’s Syndrome in an Overweight and Obese PopulationJournal of Clinical Endocrinology & Metabolism, 2009
- Bone as an endocrine organTrends in Endocrinology & Metabolism, 2009
- The Diagnosis of Cushing's Syndrome: An Endocrine Society Clinical Practice GuidelineJournal of Clinical Endocrinology & Metabolism, 2008
- Utility of Biochemical Markers of Bone Turnover and Bone Mineral Density in Management of OsteoporosisCritical Reviews in Clinical Laboratory Sciences, 2008
- Receiver-Operating Characteristic Analysis for Evaluating Diagnostic Tests and Predictive ModelsJournal of the American College of Cardiology, 2007
- Serum bone Gla protein and carboxyterminal cross-linked telopeptide of type I collagen in patients with Cushing’s syndromeHeart, 1996
- Vertebral fracture assessment using a semiquantitative techniqueJournal of Bone and Mineral Research, 1993
- Bone gla protein (osteocalcin) assay standardization reportJournal of Bone and Mineral Research, 1990